News from us and our partners

Tags

Topics

0 results

News
6 December, 2022
FMC Corporation and Micropep Technologies announce strategic collaboration to co-develop bioherbicide solutions
News
29 November, 2022
Microphyt raises €15 million to accelerate the commercialization of its microalgae-based natural solutions for nutrition and well-being
News
28 November, 2022
CinCor Pharma announces topline data for Phase 2 HALO Trial evaluating selective aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension
News
21 November, 2022
Inventiva announces a new Director of the Board of Directors
News
15 November, 2022
Moon Surgical names Mark Toland as independent board member
News
14 November, 2022
Endoron Medical awarded a €2.5M grant from the European Commission through the prestigious EIC Accelerator Program
News
9 November, 2022
DNA Script appoints Bruno Poddevin as SVP business development
News
9 November, 2022
Sofinnova Partners appoints Mats Eklund as Partner and Chief Operating Officer
News
7 November, 2022
CinCor Pharma announces publication in the New England Journal of Medicine of Phase 2 BrigHtn data on selective aldosterone synthase inhibitor baxdrostat in treatment-resistant hypertension
News
7 November, 2022
Sensorion announces US FDA grants Rare Pediatric Disease Designation to OTOF-GT for the treatment of otoferlin gene-mediated hearing loss
News
25 October, 2022
Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints
News
21 October, 2022
F2G announces data from Phase 2b study at ID Week 2022 showing positive therapeutic response in patients with invasive fungal infections treated with Olorofim
News
18 October, 2022
Noema Pharma receives FDA Fast Track designation for basimglurant (NOE-101) in trigeminal neuralgia
Feature
17 October, 2022
The origins of our Industrial Biotech strategy
News
14 October, 2022
Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners
News
13 October, 2022
Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide

FMC Corporation and Micropep Technologies announce strategic collaboration to co-develop bioherbicide solutions

Microphyt raises €15 million to accelerate the commercialization of its microalgae-based natural solutions for nutrition and well-being

CinCor Pharma announces topline data for Phase 2 HALO Trial evaluating selective aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension

Inventiva announces a new Director of the Board of Directors

Moon Surgical names Mark Toland as independent board member

Endoron Medical awarded a €2.5M grant from the European Commission through the prestigious EIC Accelerator Program

DNA Script appoints Bruno Poddevin as SVP business development

Sofinnova Partners appoints Mats Eklund as Partner and Chief Operating Officer

CinCor Pharma announces publication in the New England Journal of Medicine of Phase 2 BrigHtn data on selective aldosterone synthase inhibitor baxdrostat in treatment-resistant hypertension

Sensorion announces US FDA grants Rare Pediatric Disease Designation to OTOF-GT for the treatment of otoferlin gene-mediated hearing loss

Inotrem announces that its ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets its primary and key secondary endpoints

F2G announces data from Phase 2b study at ID Week 2022 showing positive therapeutic response in patients with invasive fungal infections treated with Olorofim

Noema Pharma receives FDA Fast Track designation for basimglurant (NOE-101) in trigeminal neuralgia

The origins of our Industrial Biotech strategy

Mablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners

Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide